Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Midecamycin (SF-837)

Midecamycin (SF-837)

Catalog No.GC32126

Midecamycin (SF-837), an acetoxy-substituted macrolide antibiotic, is tested against gram-positive and gram-negative bacteria.

Products are for research use only. Not for human use. We do not sell to patients.

Midecamycin (SF-837) Chemical Structure

Cas No.: 35457-80-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$61.00
In stock
50mg
$56.00
In stock
100mg
$82.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Midecamycin, an acetoxy-substituted macrolide antibiotic, is tested against gram-positive and gram-negative bacteria.

Midecamycin inhibits the majority of streptococci, staphylococci, and strains of Haemophilus and Listeria at concentrations of less than 3.1 μg/mL[1]. Midecamycin is a 16-membered macrolide. Midecamycin is a new macrolide antibiotic, which is produced by Streptomyces mycarofaciens[2].

[1]. Neu HC. In vitro activity of midecamycin, a new macrolide antibiotic. Antimicrob Agents Chemother. 1983 Sep;24(3):443-4. [2]. Cong L, et al. Cloning and characterization of genes encoded in dTDP-D-mycaminose biosynthetic pathway from amidecamycin-producing strain, Streptomyces mycarofaciens. Acta Biochim Biophys Sin (Shanghai). 2007 Mar;39(3):187-93.

Reviews

Review for Midecamycin (SF-837)

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Midecamycin (SF-837)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.